Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Other Operating Expenses (2023 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other Operating Expenses for 3 consecutive years, with $56.7 million as the latest value for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 648.12% year-over-year to $56.7 million; the TTM value through Mar 2026 reached $56.7 million, up 648.12%, while the annual FY2025 figure was $56.7 million, 648.12% up from the prior year.
  • Other Operating Expenses hit $56.7 million in Q4 2025 for Cartesian Therapeutics, up from $7.6 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $56.7 million in Q4 2025 and bottomed at $710000.0 in Q4 2023.
  • Average Other Operating Expenses over 3 years is $21.7 million, with a median of $7.6 million recorded in 2024.
  • Year-over-year, Other Operating Expenses surged 967.46% in 2024 and then skyrocketed 648.12% in 2025.
  • Cartesian Therapeutics' Other Operating Expenses stood at $710000.0 in 2023, then soared by 967.46% to $7.6 million in 2024, then surged by 648.12% to $56.7 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $56.7 million, $7.6 million, and $710000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.